Aktar Mert 4

What Happened

• Aktar Mert, a director of Kyverna Therapeutics (KYTX), received two awards on 2026-05-27: 5,093 restricted stock units (RSUs) and a derivative award covering 20,582 shares. Both were granted at $0.00 (no cash paid). These are awards/compensation grants (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: May 27, 2026; filing date: May 29, 2026 (filed within the standard two-business-day window).
• Price: $0.00 per share; total cash paid = $0.
• Vesting (footnotes):
  • RSUs (5,093) vest in full on the earlier of (i) May 27, 2027 or (ii) immediately prior to the issuer’s 2027 annual meeting, subject to continued service.
  • The 20,582-share derivative award will fully vest and be exercisable on the same schedule, subject to continued service.
• Shares owned after the transaction: not specified in the provided filing.
• Code: A = Award/Grant; the 20,582 entry is a derivative award (option-like grant), not an exercise or sale.

Context

• These awards are part of equity compensation and do not represent an open-market buy or sale. The derivative award is not exercised here — it is a grant that will vest (and, if applicable, become exercisable) by the stated vesting date if the director remains in service. Such grants are common for directors and are primarily a compensation/retention mechanism rather than an immediate signal of buying or selling.